Patents by Inventor John A. Kink

John A. Kink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic ribonucleases
    Patent number: 8628768
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: January 14, 2014
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
    Patent number: 8461136
    Abstract: Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: June 11, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: William E. Fahl, Nalini Raghavachari, Ming Zhu, John A. Kink
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
    Publication number: 20130078229
    Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.
    Type: Application
    Filed: October 26, 2012
    Publication date: March 28, 2013
    Inventors: John A Kink, Laura E. Strong, Mark N. Shahan
  • THERAPEUTIC RIBONUCLEASES
    Publication number: 20120276077
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Application
    Filed: July 10, 2012
    Publication date: November 1, 2012
    Applicant: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Methods and compositions for the treatment of cancer
    Patent number: 8298801
    Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: October 30, 2012
    Assignee: Quintessence Biosciences, Inc.
    Inventors: John A. Kink, Laura E. Strong, Mark N. Shahan
  • Therapeutic ribonucleases
    Patent number: 8216567
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: July 10, 2012
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • THERAPEUTIC RIBONUCLEASES
    Publication number: 20120003150
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Application
    Filed: September 13, 2011
    Publication date: January 5, 2012
    Applicant: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Therapeutic ribonucleases
    Patent number: 8029782
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: October 4, 2011
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • COMPOSITIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
    Publication number: 20100297215
    Abstract: Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents.
    Type: Application
    Filed: May 11, 2009
    Publication date: November 25, 2010
    Inventors: William E. Fahl, Nalini Raghavachari, Ming Zhu, John A. Kink
  • THERAPEUTIC RIBONUCLEASES
    Publication number: 20100080789
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Application
    Filed: October 1, 2009
    Publication date: April 1, 2010
    Applicant: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
    Patent number: 7531562
    Abstract: Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: May 12, 2009
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: William E. Fahl, Nalini Raghavachari, Ming Zhu, John A. Kink
  • COMPOSITIONS AND METHODS FOR RIBONUCLEASE-BASED THERAPEUTICS
    Publication number: 20090098101
    Abstract: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).
    Type: Application
    Filed: October 8, 2008
    Publication date: April 16, 2009
    Applicant: QUINTESSENCE BIOSCIENCES, INC.
    Inventors: Ronald T. Raines, Thomas J. Rutkoski, John A. Kink, Laura E. Strong
  • Treatment of sepsis
    Patent number: 7494652
    Abstract: Compositions and methods are described for treatment of sepsis in animals, including humans. Unique and specific combinations of polyclonal antibodies directed to cytokines are shown to have a beneficial effect in animal models predictive of human therapy.
    Type: Grant
    Filed: June 10, 1998
    Date of Patent: February 24, 2009
    Assignee: Promega Corporation
    Inventor: John A. Kink
  • Prevention and treatment of sepsis
    Publication number: 20080206259
    Abstract: Compositions and methods are described for treatment of sepsis in animals, including humans. Unique and specific combinations of polyclonal antibodies directed to cytokines are shown to have a beneficial effect in animal models predictive of human therapy.
    Type: Application
    Filed: October 30, 2007
    Publication date: August 28, 2008
    Inventor: John A. Kink
  • Methods and compositions for the treatment of cancer
    Publication number: 20080095755
    Abstract: The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.
    Type: Application
    Filed: July 17, 2007
    Publication date: April 24, 2008
    Applicant: Quintessence Biosciences, Inc.
    Inventors: John Kink, Laura Strong, Mark Shahan
  • Modified ribonucleases
    Publication number: 20080025964
    Abstract: The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).
    Type: Application
    Filed: June 25, 2007
    Publication date: January 31, 2008
    Applicant: Quintessence Biosciences, Inc.
    Inventors: John Kink, Laura Strong, Vladimir Trubetskoy, Mark Shahan
  • Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
    Patent number: 7261891
    Abstract: Methods are described for treating inflammatory bowel disease in animals, including humans. Specific avian polyclonal antibodies directed to proinflammatory cytokines (such as IL-6 and TNF) are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of colitis, including Crohn's disease.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: August 28, 2007
    Assignee: Promega Corporation
    Inventors: John A. Kink, Katherine L. Worledge, Douglas C. Stafford
  • Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
    Patent number: 7045550
    Abstract: Polyamine effectors are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more polyamine effectors formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.
    Type: Grant
    Filed: August 7, 2002
    Date of Patent: May 16, 2006
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: William E. Fahl, John Kink
  • Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
    Publication number: 20050053604
    Abstract: Methods are described for treating inflammatory bowel disease in animals, including humans. Specific avian polyclonal antibodies directed to proinflammatory cytokines (such as IL-6 and TNF) are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of colitis, including Crohn's disease.
    Type: Application
    Filed: July 25, 2003
    Publication date: March 10, 2005
    Inventors: John Kink, Katherine Worledge, Douglas Stafford
  • Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
    Publication number: 20050043224
    Abstract: Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents.
    Type: Application
    Filed: June 30, 2004
    Publication date: February 24, 2005
    Inventors: William Fahl, Nalini Raghavachari, Ming Zhu, John Kink